Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 7.6
(-2.81%)
SEK 7.6
(-2.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -151.85 Million SEK | -30.82% |
| 2023 | -116.07 Million SEK | -30.63% |
| 2022 | -88.85 Million SEK | -143.56% |
| 2021 | 204 Million SEK | 2001.22% |
| 2020 | 9.7 Million SEK | 126.43% |
| 2019 | -36.73 Million SEK | 16.43% |
| 2018 | -43.95 Million SEK | -71.99% |
| 2017 | -25.55 Million SEK | 20.16% |
| 2016 | -32 Million SEK | -49.59% |
| 2015 | -21.39 Million SEK | -33.45% |
| 2014 | -16.03 Million SEK | -26.92% |
| 2013 | -12.63 Million SEK | 75.55% |
| 2012 | -51.67 Million SEK | -150.38% |
| 2011 | 102.57 Million SEK | 30994.58% |
| 2010 | -332 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -49.74 Million SEK | -24.12% |
| 2024 Q3 | -40.07 Million SEK | -37.0% |
| 2024 Q2 | -29.25 Million SEK | 10.77% |
| 2024 Q1 | -32.78 Million SEK | 12.61% |
| 2023 Q1 | -32.43 Million SEK | 11.8% |
| 2023 FY | -116.07 Million SEK | -30.63% |
| 2023 Q4 | -37.51 Million SEK | -112.84% |
| 2023 Q3 | -17.62 Million SEK | 29.47% |
| 2023 Q2 | -24.98 Million SEK | 22.96% |
| 2022 Q4 | -36.77 Million SEK | -121.04% |
| 2022 FY | -88.85 Million SEK | -143.56% |
| 2022 Q3 | -16.63 Million SEK | -2703.44% |
| 2022 Q2 | 639 Thousand SEK | 101.69% |
| 2022 Q1 | -37.76 Million SEK | -38.61% |
| 2021 Q1 | 104.91 Million SEK | 878.14% |
| 2021 Q2 | 15.06 Million SEK | -85.64% |
| 2021 Q3 | -32.67 Million SEK | -316.92% |
| 2021 FY | 204 Million SEK | 2001.22% |
| 2021 Q4 | -27.24 Million SEK | 16.6% |
| 2020 Q1 | -6.78 Million SEK | 30.55% |
| 2020 Q3 | -7.15 Million SEK | -119.28% |
| 2020 Q4 | -13.48 Million SEK | -88.34% |
| 2020 Q2 | 37.12 Million SEK | 647.37% |
| 2020 FY | 9.7 Million SEK | 126.43% |
| 2019 Q4 | -9.76 Million SEK | -23.76% |
| 2019 Q1 | -8.52 Million SEK | 25.47% |
| 2019 FY | -36.73 Million SEK | 16.43% |
| 2019 Q2 | -10.42 Million SEK | -22.29% |
| 2019 Q3 | -7.89 Million SEK | 24.3% |
| 2018 Q3 | -12.55 Million SEK | -36.73% |
| 2018 FY | -43.95 Million SEK | -71.99% |
| 2018 Q4 | -11.43 Million SEK | 8.92% |
| 2018 Q2 | -9.18 Million SEK | 14.72% |
| 2018 Q1 | -10.77 Million SEK | -65.18% |
| 2017 FY | -25.55 Million SEK | 20.16% |
| 2017 Q4 | -6.52 Million SEK | 21.45% |
| 2017 Q1 | -4.33 Million SEK | 9.55% |
| 2017 Q2 | -6.41 Million SEK | -48.04% |
| 2017 Q3 | -8.3 Million SEK | -29.3% |
| 2016 FY | -32 Million SEK | -49.59% |
| 2016 Q1 | -4.3 Million SEK | -2.8% |
| 2016 Q2 | -4.69 Million SEK | -9.14% |
| 2016 Q3 | -18.21 Million SEK | -287.99% |
| 2016 Q4 | -4.79 Million SEK | 73.68% |
| 2015 Q4 | -4.18 Million SEK | 42.31% |
| 2015 Q3 | -7.25 Million SEK | -78.49% |
| 2015 Q2 | -4.06 Million SEK | 31.03% |
| 2015 Q1 | -5.89 Million SEK | -81.01% |
| 2015 FY | -21.39 Million SEK | -33.45% |
| 2014 Q4 | -3.25 Million SEK | 8.93% |
| 2014 Q2 | -4.38 Million SEK | 8.87% |
| 2014 Q3 | -3.57 Million SEK | 18.57% |
| 2014 Q1 | -4.81 Million SEK | -12.37% |
| 2014 FY | -16.03 Million SEK | -26.92% |
| 2013 Q1 | 907 Thousand SEK | 103.19% |
| 2013 Q4 | -4.28 Million SEK | -7.39% |
| 2013 FY | -12.63 Million SEK | 75.55% |
| 2013 Q3 | -3.99 Million SEK | 24.18% |
| 2013 Q2 | -5.26 Million SEK | -680.37% |
| 2012 Q1 | -7.69 Million SEK | 71.09% |
| 2012 Q4 | -28.42 Million SEK | -1372.59% |
| 2012 Q2 | -13.63 Million SEK | -77.22% |
| 2012 Q3 | -1.93 Million SEK | 85.84% |
| 2012 FY | -51.67 Million SEK | -150.38% |
| 2011 Q1 | 98.32 Million SEK | 31.13% |
| 2011 FY | 102.57 Million SEK | 30994.58% |
| 2011 Q2 | 74.29 Million SEK | -24.44% |
| 2011 Q3 | -43.44 Million SEK | -158.48% |
| 2011 Q4 | -26.6 Million SEK | 38.76% |
| 2010 Q2 | -26.57 Million SEK | 0.0% |
| 2010 FY | -332 Thousand SEK | 0.0% |
| 2010 Q3 | -30.95 Million SEK | -16.49% |
| 2010 Q4 | 74.98 Million SEK | 342.25% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 2cureX AB (publ) | -32.51 Million SEK | -366.972% |
| Abliva AB (publ) | -95.5 Million SEK | -58.99% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -38.945% |
| AcouSort AB (publ) | -17.08 Million SEK | -788.583% |
| Active Biotech AB (publ) | -45.8 Million SEK | -231.55% |
| Alzinova AB (publ) | -16.48 Million SEK | -821.42% |
| Amniotics AB (publ) | -30.87 Million SEK | -391.902% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -244.691% |
| Aptahem AB (publ) | -11.11 Million SEK | -1266.434% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -1083.739% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 38.915% |
| BioInvent International AB (publ) | -330.3 Million SEK | 54.027% |
| BioArctic AB (publ) | 229.24 Million SEK | 166.238% |
| Biosergen AB | -27.03 Million SEK | -461.638% |
| Biovica International AB (publ) | -124.82 Million SEK | -21.652% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -167.243% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 67.427% |
| Camurus AB (publ) | 431.44 Million SEK | 135.196% |
| Cantargia AB (publ) | -280.02 Million SEK | 45.773% |
| Corline Biomedical AB | -1.8 Million SEK | -8294.14% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -619.975% |
| CombiGene AB (publ) | -35.66 Million SEK | -325.763% |
| Cyxone AB (publ) | -22.98 Million SEK | -560.533% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -1200.308% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 53.548% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -826.029% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -66.136% |
| Fluicell AB (publ) | -26.55 Million SEK | -471.854% |
| Genovis AB (publ.) | 61.5 Million SEK | 346.911% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -33.998% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 81.743% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -23.387% |
| Mendus AB (publ) | -101.61 Million SEK | -49.431% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 14.614% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -309.619% |
| I-Tech AB | 20.2 Million SEK | 851.621% |
| Intervacc AB (publ) | -102.85 Million SEK | -47.639% |
| Kancera AB (publ) | -64.88 Million SEK | -134.015% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 2919.346% |
| LIDDS AB (publ) | -40.2 Million SEK | -277.68% |
| Lipum AB (publ) | -37.17 Million SEK | -308.44% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -1152.061% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1347.843% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -748.466% |
| Nanologica AB (publ) | -75.15 Million SEK | -102.044% |
| NextCell Pharma AB | -41.95 Million SEK | -261.894% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 39.043% |
| OncoZenge AB (publ) | -15.9 Million SEK | -854.911% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1429.203% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -819.022% |
| Saniona AB (publ) | -95.81 Million SEK | -58.491% |
| Simris Alg AB (publ) | -37.3 Million SEK | -307.05% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -259.638% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -34568.95% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -539.719% |
| SynAct Pharma AB | -215.81 Million SEK | 29.637% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 51.165% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 60.881% |
| Xintela AB (publ) | -54.08 Million SEK | -180.772% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 15.483% |
| Ziccum AB (publ) | -21.41 Million SEK | -609.182% |